Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center Observational Study to Assess Effectiveness and Safety of Fixed Dose Combination of Generic Product of Lopinavir/Ritonavir in HIV-1 Infected Patients After Switching From Kaletra® (Lopinavir/Ritonavir) for Administrative Reasons in the Routine Clinical Settings of Russian Federation (COPI)

NCT04138199 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04138199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04138199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center Observational Study to Assess Effectiveness and Safety of Fixed Dose Combination of Generic Product of Lopinavir/Ritonavir in HIV-1 Infected Patients After Switching From Kaletra® (Lopinavir/Ritonavir) for Administrative Reasons in the Routine Clinical Settings of Russian Federation (COPI)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Terminated
Start date
November 1, 2019
Completion date
July 8, 2020
Enrollment
239 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection